What did the study measure?

Memory performance in rats after an induced ethanol impairment, alongside BDNF content in the hippocampus and prefrontal cortex.

Why induce an impairment first?

It creates a defined thing to act against and a clear expected direction — a more demanding test than a screen in healthy animals.

Does a BDNF change prove causation?

No. Expression is upstream of effect, and a change in content is not evidence that it produced the behavioural difference.

Selank (Tuftsin Analogue)

An Induced-Deficit Model With a Biochemical Readout

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Kolik and colleagues reported in the Bulletin of Experimental Biology and Medicine in 2019 that Selank protected against ethanol-induced memory impairment in rats, relating the effect to BDNF content in the hippocampus and prefrontal cortex.

Key facts

Study: Kolik 2019 (PMID 31625062)
Species: Rats
Model: Ethanol-induced memory impairment
Biochemical readout: BDNF content
Regions examined: Hippocampus, prefrontal cortex
Design type: Induced deficit, then intervention

Why an induced deficit is a better test than a baseline one

Asking whether a compound improves memory in healthy animals is a poorly specified question, since performance may already be near ceiling. Inducing a defined impairment first creates something measurable to act against and a clear direction of expected effect. It is a more demanding design than an open-ended cognitive screen.

Why pairing behaviour with biochemistry matters

A behavioural difference alone shows that something changed. Measuring BDNF content alongside it in specific regions indicates where, and offers a candidate route. Reporting both allows the two levels to be checked against each other, and disagreement between them would itself be informative.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

Why those two regions

The hippocampus is central to forming new memories and the prefrontal cortex to working memory and executive control. Both are affected by ethanol. Measuring in regions relevant to the induced deficit is more interpretable than a whole-brain measurement that would average across tissue where nothing was expected to happen.

The recurring caution about BDNF

BDNF appears throughout peptide research because it is measurable, responsive and plausibly connected to almost anything neural. Expression sits upstream of effect, and a change in content is not by itself evidence that the change caused the behavioural difference. This site makes the same point about the Semax literature, and it applies identically here.

The limits of the model

Acute ethanol-induced impairment in rats is a tool for producing a defined deficit, not a model of any human condition. It says nothing about alcohol consumption, intoxication or its consequences in people, and it was not designed to.

What is not claimed

Anything about memory, alcohol or cognition in any person. Selank holds no marketing authorisation from the MHRA, EMA or FDA, and material supplied here is for laboratory research only. Nothing here treats or mitigates the effects of alcohol in anyone.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What did the study measure?: Memory performance in rats after an induced ethanol impairment, alongside BDNF content in the hippocampus and prefrontal cortex.
Why induce an impairment first?: It creates a defined thing to act against and a clear expected direction — a more demanding test than a screen in healthy animals.
Does a BDNF change prove causation?: No. Expression is upstream of effect, and a change in content is not evidence that it produced the behavioural difference.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum